Does the Hib vaccine in Kenya deserve public money?
Haemophilus influenzae type b (Hib) vaccine was licensed for use in infants in 1991. However, developing countries delayed its introduction due to cost and because Hib disease was perceived to be relatively rare. In 2001, Kenya was one of nine countries to receive financial backing to introduce the vaccine. How cost-effective has it been? Researchers led by the Kenya Medical Research Institute (KEMRI) estimated the cost-effectiveness of delivering the Hib vaccine in Kenya. The vaccine was financed by GAVI (previously the Global Alliance for Vaccines and Immunization). It was incorporated into Kenya’s routine infant immunisation services within the pentavalent (five-in-one) vaccine which also includes diphtheria, tetanus, pertussis (whooping cough) and hepatitis B. Recently the Kenyan government agreed to co-finance the costs of the vaccine from 2006 to 2011, gradually increasing its contributions. The researchers compared the current costs of delivering the pentavalent vaccine against
Related Questions
- If the Austin Public Library Friends Foundation raises money would the cost to the tax payer be less than the original $90 million in bonds?
- United Kingdom: Why do public sector workers in the UK feel they deserve a better pension than private sector workers?
- How much money will be needed for public financing of campaigns in California?
